Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15721207 | 0.84 | OPRM1 (0.42) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8171686 | 0.83 | MAPT (0.39) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1286861 | 0.81 | USP2 (0.44) | ALDH1A1TSHRNAMPT | |
| SCHEMBL1286799 | 0.81 | BLM (0.48) | ALDH1A1TSHRLMNAPOLB | |
| SCHEMBL14725161 | 0.80 | HRH3 (0.47) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16369922 | 0.80 | ALDH1A1 (0.43) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1634121 | 0.80 | ALDH1A1 (0.46) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28501010 | 0.79 | SMN1; SMN2 (0.38) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1634763 | 0.78 | ALDH1A1 (0.49) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1635627 | 0.78 | ALDH1A1 (0.49) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223136-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | WO | disclosed |
| CN-104520290-B | Amido spirocyclic amide and sulfonamide derivatives | 基因科技股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | MAPT 474/4885CYP3A4 2383/4885CYP2D6 2350/4885 |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | HRH3, HRH2, HRH4 | MAPT 1783/4885CYP3A4 2811/4885CYP2D6 2348/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | MAPT 474/4885CYP3A4 2383/4885CYP2D6 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.